文献速递妇科

宫颈胃型腺癌:临床结局与基因组驱动因素

Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
PubMed 文献 · Gynecol Oncol · 2022-10-15

该研究回顾性分析了2002年6月1日至2019年7月1日在一家大型癌症中心诊断的70例宫颈胃型腺癌(GEA)患者,其中43例在本院接受初始治疗。Ⅰ期患者的中位无进展生存期(PFS)为107个月,中位总生存期(OS)为111个月;Ⅱ-Ⅳ期患者的中位PFS为17个月,中位OS为33个月。二代测序(NGS)显示4例(14%)存在ERBB2改变,其中2例接受了曲妥珠单抗治疗。

要点

  • GEA是一种侵袭性宫颈癌,Ⅱ期及以后诊断时PFS和OS较差。
  • Ⅰ期GEA的中位PFS为107个月,中位OS为111个月。
  • Ⅱ-Ⅳ期GEA的中位PFS为17个月,中位OS为33个月。

核心结论

  • GEA是一种侵袭性宫颈癌,Ⅱ期或更晚诊断时PFS和OS较差;需要进一步研究以确定这种罕见亚型的最佳管理方法。

研究设计与样本

  • 回顾性研究,从临床病历中获取2002年6月1日至2019年7月1日期间诊断为GEA的所有患者(共70例女性)的临床和人口学信息,其中43例在本院接受初始治疗;采用Kaplan-Meier生存分析描述PFS和OS;对部分患者的肿瘤进行NGS分析。

主要发现

  • 43例在本院接受初始治疗的患者中,4例(9%)仅接受手术,15例(35%)接受手术加辅助治疗,10例(23%)接受根治性同步放化疗(CCRT),7例(16%)仅接受化疗,3例(7%)接受新辅助CCRT加子宫切除术(伴或不伴化疗)。
  • 14例(三分之一)患者出现疾病进展,其中12例(86%)既往接受过CCRT。
  • Ⅰ期GEA患者的中位PFS为107个月(95% CI 14.8-199.2个月),中位OS为111个月(95% CI 17-205.1个月);Ⅱ-Ⅳ期患者的中位PFS为17个月(95% CI 5.6-28.4个月),中位OS为33个月(95% CI 28.2-37.8个月)。
  • NGS显示4例(14%)存在ERBB2改变,其中2例接受了曲妥珠单抗治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Gastric-type endocervical adenocarcinoma (GEA) is a rare form of cervical cancer not associated with human papilloma virus (HPV) infection. We summarize our experience with GEA at a large cancer center. METHODS: Clinical and demographic information on all patients diagnosed with GEA between June 1, 2002 and July 1, 2019 was obtained retrospectively from clinical charts. Kaplan-Meier survival analysis was performed to describe progression-free survival (PFS) and overall survival (OS). Tumors from a subset of patients underwent next generation sequencing (NGS) analysis. RESULTS: A total of 70 women with GEA were identified, including 43 who received initial treatment at our institution: of these 4 (9%) underwent surgery alone, 15 (35%) underwent surgery followed by adjuvant therapy, 10 (23%) were treated with definitive concurrent chemoradiation (CCRT), 7 (16%) with chemotherapy alone, and 3 (7%) with neoadjuvant CCRT and hysterectomy with or without chemotherapy. One-third (n = 14) of patients experienced disease progression, of whom 86% (n = 12) had prior CCRT. The median PFS and OS for patients with stage I GEA were 107 months (95% CI 14.8-199.2 months) and 111 months (95% CI 17-205.1 months) respectively, compared to 17 months (95% CI 5.6-28.4 months) and 33 months (95% CI 28.2-37.8 months) for patients with stages II-IV, respectively. On NGS, 4 patients (14%) had ERBB2 alterations, including 2 patients who received trastuzumab. CONCLUSIONS: GEA is an aggressive form of cervical cancer with poor PFS and OS when diagnosed at stage II or later. Further investigation is needed to identify the optimal management approach for this rare subtype.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ehmann S, Sassine D, Straubhar AM, et al. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. Gynecol Oncol. 2022. PMID: 36253302. doi:10.1016/j.ygyno.2022.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。